Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction

ID#: NCT04112186

Age: 18 - 64 years

Gender: All

Healthy Subjects: Accepts Healthy Volunteers

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: October 21, 2020

End Date: June 01, 2024

Contact Information:
Gabriela S Hoberman, BA
(212) 241-0965
Pias Malaker
212-241-2545
Summary: In this study, neuroimaging of reward processing, drug cue reactivity and inhibitory control is used before and immediately after 8 weeks of two types of group therapy in individuals with opioid addiction; clinical outcomes will be assessed before, immediately and three months after treatment. Results could point to factors that track and predict recovery with treatment, offering clinicians markers that can be used for enhancing precision medicine with the goal of reducing morbidity and mortality associated with opiate addiction.
Eligibility:

Inclusion Criteria:

- Ability to understand and give informed consent

- Males and Females 18-64 years of age

- DSM-5 diagnosis of OUD with heroin as the primary drug of choice

- Stabilized on methadone or other form of MAT. Inclusion criteria for healthy controls:

- The same as inclusion criteria 1-2 above; dependence on nicotine or caffeine is non-exclusionary.

Exclusion Criteria:

- DSM-5 diagnosis for schizophrenia or developmental disorder (e.g., autism)

- Head trauma with loss of consciousness

- History of neurological disease of central origin including seizures

- Cardiovascular disease including high blood pressure and/or other medical conditions, including metabolic, endocrinological,oncological or autoimmune diseases, and infectious diseases common in iOUD including Hepatitis B and C or HIV/AIDS

- Metal implants or other MR contraindications Exclusion criteria for healthy control subjects:

- The same, except history of any drug use disorder is prohibitive.
Find a Clinical Trial Find Cancer Clinical Trials